JANSSEN PRODS Company Profile
✉ Email this page to a colleague
What is the competitive landscape for JANSSEN PRODS, and what generic alternatives to JANSSEN PRODS drugs are available?
JANSSEN PRODS has eight approved drugs.
There are twenty-three US patents protecting JANSSEN PRODS drugs.
There are seven hundred and eighty-seven patent family members on JANSSEN PRODS drugs in sixty-four countries and two hundred and forty-eight supplementary protection certificates in nineteen countries.
Summary for JANSSEN PRODS
| International Patents: | 787 |
| US Patents: | 23 |
| Tradenames: | 7 |
| Ingredients: | 6 |
| NDAs: | 8 |
Drugs and US Patents for JANSSEN PRODS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Janssen Prods | EDURANT | rilpivirine hydrochloride | TABLET;ORAL | 202022-001 | May 20, 2011 | RX | Yes | Yes | 7,125,879*PED | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Janssen Prods | EDURANT PED | rilpivirine hydrochloride | TABLET, FOR SUSPENSION;ORAL | 219016-001 | Mar 15, 2024 | DISCN | Yes | No | 11,065,198 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Janssen Prods | OLYSIO | simeprevir sodium | CAPSULE;ORAL | 205123-001 | Nov 22, 2013 | DISCN | Yes | No | 9,040,562 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| Janssen Prods | PREZISTA | darunavir | TABLET;ORAL | 021976-004 | Dec 18, 2008 | RX | Yes | No | 7,700,645*PED | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Janssen Prods | EDURANT PED | rilpivirine hydrochloride | TABLET, FOR SUSPENSION;ORAL | 219016-001 | Mar 15, 2024 | DISCN | Yes | No | 7,125,879 | ⤷ Subscribe | Y | Y | ⤷ Subscribe | ||
| Janssen Prods | PREZISTA | darunavir | TABLET;ORAL | 021976-001 | Jun 23, 2006 | DISCN | Yes | No | 8,518,987*PED | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| Janssen Prods | PREZCOBIX | cobicistat; darunavir | TABLET;ORAL | 205395-001 | Jan 29, 2015 | RX | Yes | Yes | 10,039,718 | ⤷ Subscribe | Y | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for JANSSEN PRODS
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Janssen Prods | PREZISTA | darunavir | TABLET;ORAL | 021976-006 | Nov 9, 2012 | 5,843,946*PED | ⤷ Subscribe |
| Janssen Prods | PREZISTA | darunavir | TABLET;ORAL | 021976-004 | Dec 18, 2008 | RE43802*PED | ⤷ Subscribe |
| Janssen Prods | PREZISTA | darunavir | TABLET;ORAL | 021976-005 | Dec 18, 2008 | RE43596*PED | ⤷ Subscribe |
| Janssen Prods | EDURANT | rilpivirine hydrochloride | TABLET;ORAL | 202022-001 | May 20, 2011 | 7,067,522 | ⤷ Subscribe |
| Janssen Prods | PREZISTA | darunavir | TABLET;ORAL | 021976-005 | Dec 18, 2008 | 6,335,460*PED | ⤷ Subscribe |
| Janssen Prods | PREZISTA | darunavir | SUSPENSION;ORAL | 202895-001 | Dec 16, 2011 | RE43596*PED | ⤷ Subscribe |
| Janssen Prods | PREZISTA | darunavir | TABLET;ORAL | 021976-005 | Dec 18, 2008 | 6,703,403*PED | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
Paragraph IV (Patent) Challenges for JANSSEN PRODS drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 800 mg | ➤ Subscribe | 2013-05-14 |
International Patents for JANSSEN PRODS Drugs
| Country | Patent Number | Estimated Expiration |
|---|---|---|
| Japan | 2011231132 | ⤷ Subscribe |
| Denmark | 3150586 | ⤷ Subscribe |
| African Regional IP Organization (ARIPO) | 3639 | ⤷ Subscribe |
| Denmark | 2487166 | ⤷ Subscribe |
| Portugal | 2744810 | ⤷ Subscribe |
| Norway | 2017065 | ⤷ Subscribe |
| South Africa | 201400582 | ⤷ Subscribe |
| >Country | >Patent Number | >Estimated Expiration |
Supplementary Protection Certificates for JANSSEN PRODS Drugs
| Patent Number | Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|---|
| 2487163 | 381 2-2017 | Slovakia | ⤷ Subscribe | PRODUCT NAME: KOBICISTAT VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM/ATAZANAVIR VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/15/1025 20150715 |
| 2487163 | 1790002-8 | Sweden | ⤷ Subscribe | PRODUCT NAME: COBICISTAT OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF AND ATAZANAVIR OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR ATAZANAVIR SULFATE; FIRST MARKETING AUTHORIZATION NUMBER SE: EG EU/1/15/1025, 2015-07-15 |
| 1419152 | SPC/GB12/025 | United Kingdom | ⤷ Subscribe | PRODUCT NAME: A COMBINATION OF RILPIVIRINE, A N-OXIDE, A PHARMACEUTICALLY ACCEPTABLE ADDITION SALT INCLUDING THE HYDROCHLORIC ACID SALT, OR A QUATERNARY AMINE THEREOF, AND TENOFOVIR, IN PARTICULAR TENOFOVIR DISOPROXIL FUMARATE.; REGISTERED: UK EU/1/11/737/001 20111128 |
| 1419152 | PA2012009,C1419152 | Lithuania | ⤷ Subscribe | PRODUCT NAME: RILPIVIRINUM + TENOFOVIRUM DISOPROXILUM; REGISTRATION NO/DATE: EU/1/11/737/001, 2011 11 28 EU/1/11/737/002 20111128 |
| 1632232 | 93384 | Luxembourg | ⤷ Subscribe | PRODUCT NAME: COMBINAISON DE CHLORHYDRATE DE RILPIVIRINE OU UNE FORME THERAPEUTIQUE EQUIVALENTE QUI EN DERIVE TELLE QUE PROTEGEE PAR LE BREVET DE BASE, ET TENOFOVIR ALAFENAMIDE, OU UN SEL PHARMACEUTIQUEMENT ACCEPTABLE DE CELUI-CI, EN PARTICULIER LE FUMARATE DE TENOFOVIR ALAFENAMIDE; AUTHORISATION NUMBER AND DATE: EU/1/16/1112 ODEFSEY - EMTRICITABINE |
| 2049506 | C02049506/01 | Switzerland | ⤷ Subscribe | PRODUCT NAME: COBICISTAT; REGISTRATION NO/DATE: SWISSMEDIC-ZULASSUNG 62673 18.10.2013 |
| 2487162 | 122016000103 | Germany | ⤷ Subscribe | PRODUCT NAME: COBICISTAT ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ ODER SOLVAT DAVON UND DARUNAVIR ODER EIN PHARMAZEUTISCH AKZEPTABLES SALZ ODER SOLVAT DAVON; REGISTRATION NO/DATE: EU/1/14/967 20141119 |
| >Patent Number | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration | >SPC Description |
Similar Applicant Names
Applicants may be listed under multiple names.
Here is a list of applicants with similar names.
Here is a list of applicants with similar names.
